Want to see IDYA full AI Analyst Report?
IDYA Stock Chart & Stats
$35.40
-$0.83(-2.29%)
At close: 4:00 PM EDT
$35.40
-$0.83(-2.29%)
Day’s Range― - ―
52-Week Range$23.23 - $40.58
Previous CloseN/A
Volume901.71K
Average Volume (3M)1.20M
Market Cap
$3.53B
Enterprise Value$2.63K
Total Cash (Recent Filing)$828.96M
Total Debt (Recent Filing)$29.31M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Nov 10, 2026EPS Estimate
-1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding96,489,490
10 Day Avg. Volume777,077
30 Day Avg. Volume1,197,127
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)2.99
Price to Sales (P/S)13.99
P/FCF Ratio-41.64
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$51.55Price Target Upside45.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-4.57
Revenue Forecast (FY)$38.33M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and over $1.2B in equity/assets provide durable financial flexibility to fund multi-year oncology programs. This reduces insolvency risk, allows sustained R&D investment through clinical readouts, and cushions the company against typical biotech volatility.
Revenue Momentum / Q2 BeatQuarterly beat and sharply accelerating TTM revenue reflect growing collaboration and partnering traction. Sustained top-line momentum is a durable signal that the company is converting science into partner-funded activity and milestone recognition, improving funding optionality beyond equity.
Clinical & Partnership CatalystsPositive registrational data with FDA Real‑Time Oncology Review and a strategic Roche collaboration materially de‑risk key programs. These structural advances increase chances of regulatory approval, validate the science to partners, and open co-development and commercialization pathways.
Bears Say
Sustained Cash BurnPersistently negative operating and free cash flow means the business is not yet self-funding. Even with improvement, ongoing burn requires continual financing or milestone receipts, forcing prioritization of programs and exposing the company to funding timing risk across multiple quarters.
Large Ongoing LossesDeep, sustained net losses and negative margins indicate the company is far from profitability. This depresses returns on invested capital, increases dependence on external funding, and can limit resources for scaling commercial operations until one or more programs achieve approval and generate product revenue.
Revenue Model Dependence On CollaborationsAs a clinical‑stage company with no marketed products, revenue is contingent on upfront, R&D funding, and milestone payments from partners. That model creates durable revenue volatility tied to partner choices, trial outcomes, and timing of milestones rather than predictable product sales.
IDEAYA Biosciences News
IDYA FAQ
What was Ideaya Biosciences’s price range in the past 12 months?
Ideaya Biosciences lowest stock price was $23.23 and its highest was $40.58 in the past 12 months.
What is Ideaya Biosciences’s market cap?
Ideaya Biosciences’s market cap is $3.53B.
When is Ideaya Biosciences’s upcoming earnings report date?
Ideaya Biosciences’s upcoming earnings report date is Nov 10, 2026 which is in 82 days.
How were Ideaya Biosciences’s earnings last quarter?
Ideaya Biosciences released its earnings results on Aug 04, 2026. The company reported -$1.22 earnings per share for the quarter, missing the consensus estimate of -$1.057 by -$0.163.
Is Ideaya Biosciences overvalued?
According to Wall Street analysts Ideaya Biosciences’s price is currently Undervalued.
Does Ideaya Biosciences pay dividends?
Ideaya Biosciences does not currently pay dividends.
What is Ideaya Biosciences’s EPS estimate?
Ideaya Biosciences’s EPS estimate is -1.18.
How many shares outstanding does Ideaya Biosciences have?
Ideaya Biosciences has 96,489,490 shares outstanding.
What happened to Ideaya Biosciences’s price movement after its last earnings report?
Ideaya Biosciences reported an EPS of -$1.22 in its last earnings report, missing expectations of -$1.057. Following the earnings report the stock price went up 2.006%.
Which hedge fund is a major shareholder of Ideaya Biosciences?
Currently, no hedge funds are holding shares in IDYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IDEAYA Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.55 (45.61% Upside)
$51.55 (45.61% Upside)
Blogger Sentiment
Bullish
IDYA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 328.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
25.78%
Trailing 12-Months
Company Description
Ideaya Biosciences
IDEAYA Biosciences, Inc. (IDYA) is a clinical-stage precision oncology company in the biotechnology sector focused on discovering and developing targeted therapeutics and molecular diagnostics for genetically defined cancers. The company’s pipeline is built around synthetic lethality and other precision-medicine approaches, with drug candidates designed to treat patient populations selected by specific tumor biomarkers.
IDYA Stock 12 Month Forecast
Average Price Target
$51.55
▲(45.61% Upside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Celcuity
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Ownership Overview
0.81% Insiders
27.51% Mutual Funds
33.18% Other Institutional Investors
23.20% Public Companies and
Individual Investors